NY-ESO-1 protein

BIOLOGICAL2 trials

Sponsors

Ludwig Institute for Cancer Research

Conditions

Malignant MelanomaTransitional Cell Carcinoma

Phase 1

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

CompletedNCT00070070

Ludwig Institute for Cancer ResearchTransitional Cell Carcinoma

Start: 2003-10-28End: 2013-09-30Updated: 2022-10-12

NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)

CompletedNCT00142454

Ludwig Institute for Cancer ResearchMalignant Melanoma

Start: 2005-08-24End: 2006-04-25Updated: 2022-10-10